Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
about
Efficacy of Transcranial Magnetic Stimulation (TMS) in the Treatment of Schizophrenia: A Review of the Literature to DateBrain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter SystemsTranslating the MAM model of psychosis to humansTowards medication-enhancement of cognitive interventions in schizophreniaNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaHow Schizophrenia Develops: Cognitive and Brain Mechanisms Underlying Onset of PsychosisEpigenetic reprogramming of cortical neurons through alteration of dopaminergic circuits.The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors.Are we studying and treating schizophrenia correctly?Using computational patients to evaluate illness mechanisms in schizophrenia.The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatmentTheranostic Biomarkers for SchizophreniaThe impact of common dopamine D2 receptor gene polymorphisms on D2/3 receptor availability: C957T as a key determinant in putamen and ventral striatum.Disruption of Akt signaling decreases dopamine sensitivity in modulation of inhibitory synaptic transmission in rat prefrontal cortex.Positron emission tomography molecular imaging for drug development.Schizophrenia: an integrated sociodevelopmental-cognitive model.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.The role of rodent models in the discovery of new treatments for schizophrenia: updating our strategy.PharmGKB summary: dopamine receptor D2Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia.Comparison of cerebral blood flow in oral somatic delusion in patients with and without a history of depression: a comparative case seriesThe promise of biological markers for treatment response in first-episode psychosis: a systematic review.Prolactin-a biomarker for antipsychotic treatment response?Translating glutamate: from pathophysiology to treatment.Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive DisordersPredicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationshipStriatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m)Tc]-TRODAT-1 and a meta-analysisTreatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive.Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study.From the prodrome to chronic schizophrenia: the neurobiology underlying psychotic symptoms and cognitive impairmentsDopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study.Dopaminergic function in the psychosis spectrum: an [18F]-DOPA imaging study in healthy individuals with auditory hallucinations.Glutamate and dopamine in schizophrenia: an update for the 21st centuryEstablishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.The nature of dopamine dysfunction in schizophrenia and what this means for treatment.Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis.Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging studyMolecular imaging as a guide for the treatment of central nervous system disordersShort-term Effects of Risperidone Monotherapy on Spontaneous Brain Activity in First-episode Treatment-naïve Schizophrenia Patients: A Longitudinal fMRI Study.
P2860
Q26782386-397A6301-9DD0-4C77-B8F8-D226412EF234Q26786247-63ABB10B-7793-4CB4-AF99-CEFEF58B3BF3Q26860217-58FAD07F-1C84-433D-BB35-2069903D02EBQ26860777-AFB425E7-3AC9-492E-8944-513D933E8EDEQ27026382-BEDC2ACA-50A4-48E2-B68E-6711CACB30C5Q28087255-BBB7C063-4891-4805-AA34-A534B2939660Q30413207-053AEEFB-ACB5-4362-AEA8-65427C7C325DQ30437188-087B55C9-E907-488C-82DA-C5A7FF247AC8Q30453020-3EC4080C-D0F9-46E5-ABDD-D83CF037ABBCQ30465313-BDE30216-7B3F-43C1-BDDD-C86AD4C66DD4Q30500752-5E0F2133-6725-487B-8D37-9F314C0F0A3CQ33593061-E5A8C453-1FC1-419E-86CF-6754D24C6056Q33624412-D6B8A16C-FF29-4910-A4AD-EF6FAF3B1EA1Q33635632-54DC2C47-1E41-41A9-8FA9-91E092E7A2C7Q33893744-A7D10EFA-97DB-4032-966C-E1C9488B74DAQ33991881-85B773E6-D96E-4CE7-AC52-D12F0D3AC56FQ34023115-4FF5603E-CC3A-463A-8382-ED56BAF24C10Q34131354-9115E31C-A16A-4638-BD29-B5F3644AFADFQ34140126-C1B0C50F-9E31-4A1B-A3C8-1CCA2CDF8C3AQ34970259-8CDF4332-3087-4F31-B70A-2B8A34E548A1Q35096515-EB09E0CA-6E76-41F2-9529-57F4985F8CE5Q35190797-258B897F-CD11-4E70-B38C-53FEDAA61288Q35369988-DFE0DE04-0CBD-4564-9D19-BBEF748D5D60Q35559926-CEE643FF-A924-48F4-8B86-CFD8CB3617F4Q35739457-9D491419-8E75-446C-BEDD-775DF1E16D90Q35795738-05B69985-436C-4549-9908-37C1BC8DC6FEQ35866868-22F40FC7-55CA-4A6E-B3B9-EB0814D89C9AQ36621010-D0F9DA3D-7C36-4CFF-9137-CA528DB15A4BQ36817154-AF751850-BF86-4B11-874B-42CBC7169DD7Q36871782-8075ECD3-D4A6-4D88-9302-58E6A39AA9B0Q36872150-B8E90413-63DA-43C6-96A7-2750697B8FD8Q36928703-215901E6-9B69-47F1-8AEC-9970FBBD4D79Q36939999-90A13580-82A1-4B56-BDC4-60414DFFB8EBQ36992322-C856A83A-47A9-4590-84DF-B05E3DC6A652Q36994341-BB8ADC76-8CC6-48D8-8F7D-C0B4C6C2DD7CQ37062793-1098DDE2-F7E9-4E06-ACB5-AF414926CF70Q37228333-BCED8A8D-89FB-421D-A9EA-CC44B6B5F62BQ37256211-A0DEEC15-D974-4F5E-AD77-D3F49BADF38FQ37262953-C8034123-A72C-491E-9817-23E0AB8360F6Q37307572-7DAEB3D2-3906-4A8F-8C61-EFE661F46B72
P2860
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Mechanisms underlying psychosi ...... ts from PET and SPECT imaging.
@en
type
label
Mechanisms underlying psychosi ...... ts from PET and SPECT imaging.
@en
prefLabel
Mechanisms underlying psychosi ...... ts from PET and SPECT imaging.
@en
P2860
P50
P1476
Mechanisms underlying psychosi ...... hts from PET and SPECT imaging
@en
P2093
P2860
P304
P356
10.2174/138161209788957528
P577
2009-01-01T00:00:00Z